Firefly BioWorks has won a $2M Phase II small business innovation research (SBIR) grant from the National Cancer Institute (NCI).
Subscribe to our email newsletter
Firefly will utilize the grant to braden its production capacity and also to assess its microRNA assay.
MicroRNAs are a class of biomarkers which are used as indicators for early diagnosis of cancer and other diseases.
Firefly BioWorks co-founder and CTO Daniel Pregibon said they look forward to work with their academic and industry partners to develop research tools in this field.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.